Insider Selling: Ascendis Pharma A/S (NASDAQ:ASND) SVP Sells $810,570.00 in Stock

Ascendis Pharma A/S (NASDAQ:ASND) SVP Mads Bodenhoff sold 3,000 shares of the stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $270.19, for a total value of $810,570.00. Following the completion of the sale, the senior vice president owned 3,000 shares in the company, valued at approximately $810,570. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Ascendis Pharma A/S Price Performance

ASND opened at $263.52 on Friday. The business has a fifty day moving average of $257.42 and a 200 day moving average of $242.12. Ascendis Pharma A/S has a 52-week low of $186.05 and a 52-week high of $282.15. The company has a quick ratio of 2.32, a current ratio of 2.99 and a debt-to-equity ratio of 0.27. The stock has a market cap of $16.44 billion, a P/E ratio of 20.44 and a beta of 0.35.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings data on Friday, August 14th. The biotechnology company reported $1.03 EPS for the quarter, missing the consensus estimate of $1.71 by ($0.68). Ascendis Pharma A/S had a net margin of 70.99% and a return on equity of 32.54%. The business had revenue of $387.22 million during the quarter, compared to the consensus estimate of $376.75 million. As a group, sell-side analysts anticipate that Ascendis Pharma A/S will post 5.15 EPS for the current year.

Institutional Trading of Ascendis Pharma A/S

Hedge funds have recently added to or reduced their stakes in the business. Cetera Investment Advisers purchased a new position in Ascendis Pharma A/S during the 2nd quarter valued at about $552,000. Rhumbline Advisers boosted its stake in shares of Ascendis Pharma A/S by 4.0% during the second quarter. Rhumbline Advisers now owns 1,441 shares of the biotechnology company’s stock valued at $249,000 after purchasing an additional 55 shares in the last quarter. Daiwa Securities Group Inc. raised its stake in Ascendis Pharma A/S by 66.2% in the second quarter. Daiwa Securities Group Inc. now owns 3,737 shares of the biotechnology company’s stock worth $645,000 after buying an additional 1,488 shares in the last quarter. Qube Research & Technologies Ltd boosted its position in Ascendis Pharma A/S by 83.4% during the 2nd quarter. Qube Research & Technologies Ltd now owns 201,044 shares of the biotechnology company’s stock valued at $34,700,000 after acquiring an additional 91,412 shares in the last quarter. Finally, Squarepoint Ops LLC purchased a new position in shares of Ascendis Pharma A/S in the 2nd quarter valued at $897,000.

Analysts Set New Price Targets

ASND has been the topic of several recent analyst reports. Stifel Nicolaus reduced their price target on shares of Ascendis Pharma A/S from $328.00 to $326.00 and set a “buy” rating on the stock in a research note on Monday, August 31st. Morgan Stanley lowered their price objective on shares of Ascendis Pharma A/S from $275.00 to $273.00 and set an “overweight” rating for the company in a research report on Tuesday, September 1st. Weiss Ratings upgraded shares of Ascendis Pharma A/S from a “sell (d)” rating to a “hold (c)” rating in a research note on Wednesday, July 15th. Jefferies Financial Group reduced their target price on shares of Ascendis Pharma A/S from $333.00 to $330.00 and set a “buy” rating on the stock in a research report on Monday, August 31st. Finally, Bank of America decreased their price target on shares of Ascendis Pharma A/S from $306.00 to $304.00 and set a “buy” rating for the company in a research note on Monday, August 31st. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $310.00.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S (NASDAQ:ASND) is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases. The company uses its proprietary TransCon technology platform to design long-acting medicines intended to improve the effectiveness, convenience, and tolerability of established treatments.

Ascendis’ marketed products include Skytrofa (lonapegsomatropin-tcgd), a long-acting growth hormone approved for the treatment of growth hormone deficiency in children, and Yorvipath (palopegteriparatide), a hormone replacement therapy for adults with hypoparathyroidism.